RG-6524

N/A

Report date: 2026/03/19 17:16:31

Base Information

Drug NameRG-6524
Drug Alias NameRO-7616789ALPS-12RG6524
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionDelta-like protein 3 modulatorsT cell surface glycoprotein CD3 modulatorsTumor necrosis factor receptor superfamily member 9 modulators
TargetsDelta-like protein 3T cell surface glycoprotein CD3Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPoland +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ag
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdF. Hoffmann-La Roche Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A